Were Gregg Williams’ Vivani Medical (VANI) share purchases open-market or private transactions?

The purchases were private sale transactions, not regular open-market buys. Footnotes state they were made under share purchase agreements dated May 12, 2025 and August 11, 2025, with prices based on the last reported Nasdaq sale prices immediately before those agreement dates.

What prices did Gregg Williams pay for his Vivani Medical (VANI) share purchases?

He paid $1.03 per share for 1,601,941 Vivani shares and $1.26 per share for 264,551 shares. The filing notes these prices matched the last reported Nasdaq sale prices for Vivani stock immediately before the respective share purchase agreement dates.

Form 4: Williams Gregg reports purchase transactions in VANI

Filing Impact

(Very High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Williams Gregg reported open-market purchase transactions in a Form 4 filing for VANI. The filing lists transactions totaling 1,866,492 shares at a weighted average price of $1.06 per share. Following the reported transactions, holdings were 29,517,401 shares.

Insider Trade Summary

Net Buyer: 1,866,492 shares ($1,983,333)

Net Buy 3 txns

Insider Williams Gregg

Role Director, 10% Owner

Bought 1,866,492 shs ($1.98M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,601,941	$1.03	$1.65M
Purchase	Common Stock	264,551	$1.26	$333K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 29,517,401 shares (Indirect, See footnote); Common Stock — 4,799,200 shares (Direct)

Footnotes (1)

The reporting person purchased 1,601,941 shares of the Issuer's common stock in a private sale transaction as disclosed in the Share Purchase Agreement dated as of May 12, 2025 at a price of $1.03 per share, which was the last reported sale price of the Issuer's common stock on the Nasdaq on May 9, 2025 (three days immediately prior to May 12, 2025). The gross proceeds from this private sale transaction were $1,649,999.23. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in the transaction set forth in this footnote. The reporting person purchased 264,551 shares of the Issuer's common stock in a private sale transaction as disclosed in the Share Purchase Agreement dated as of August 11, 2025 at a price of $1.26 per share, which was the last reported sale price of the Issuer's common stock on the Nasdaq on August 10, 2025 (the day immediately prior to August 11, 2025). The gross proceeds from this private sale transaction were $333,334.26. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in the transaction set forth in this footnote. The reporting person owns 34,581,152 shares directly and/or indirectly as follows: (i) 4,799,200 shares of common stock owned by the reporting person, (ii) 27,656,200 shares of common stock owned by Gregg G. Williams 2006 Trust, (iii) 1,212,856 shares of common stock owned by Williams International Co. LLC, (iv) 181,587 shares of common stock owned by Sam Williams Family Investments LLC, and (v) 731,309 shares of common stock owned by Sam B. Williams 1995 Generation-Skipping Trust. Gregg Williams has voting and dispositive power over all of these shares.

Form 4 Insider Transactions: What Each Field Means →

02/17/2026 - 06:01 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Gregg

(Last)

(First)

(Middle)

C/O VIVANI MEDICAL, INC.

1350 S. LOOP ROAD

(Street)

ALAMEDA

94502

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vivani Medical, Inc. [ VANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/15/2026		P⁽¹⁾		1,601,941	A	$1.03	29,517,401	I	See footnote⁽³⁾
Common Stock	02/15/2026		P⁽²⁾		264,551	A	$1.26	29,781,952	I	See footnote⁽³⁾
Common Stock								4,799,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reporting person purchased 1,601,941 shares of the Issuer's common stock in a private sale transaction as disclosed in the Share Purchase Agreement dated as of May 12, 2025 at a price of $1.03 per share, which was the last reported sale price of the Issuer's common stock on the Nasdaq on May 9, 2025 (three days immediately prior to May 12, 2025). The gross proceeds from this private sale transaction were $1,649,999.23. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in the transaction set forth in this footnote.

2. The reporting person purchased 264,551 shares of the Issuer's common stock in a private sale transaction as disclosed in the Share Purchase Agreement dated as of August 11, 2025 at a price of $1.26 per share, which was the last reported sale price of the Issuer's common stock on the Nasdaq on August 10, 2025 (the day immediately prior to August 11, 2025). The gross proceeds from this private sale transaction were $333,334.26. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in the transaction set forth in this footnote.

3. The reporting person owns 34,581,152 shares directly and/or indirectly as follows: (i) 4,799,200 shares of common stock owned by the reporting person, (ii) 27,656,200 shares of common stock owned by Gregg G. Williams 2006 Trust, (iii) 1,212,856 shares of common stock owned by Williams International Co. LLC, (iv) 181,587 shares of common stock owned by Sam Williams Family Investments LLC, and (v) 731,309 shares of common stock owned by Sam B. Williams 1995 Generation-Skipping Trust. Gregg Williams has voting and dispositive power over all of these shares.

	/s/ Anthony Baldor, Attorney-in-fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Gregg Williams report for Vivani Medical (VANI)?

Gregg Williams reported two private purchases of Vivani Medical common stock. He acquired 1,601,941 shares at $1.03 per share and 264,551 shares at $1.26 per share, both tied to previously dated share purchase agreements described in the filing footnotes.

How many Vivani Medical (VANI) shares does Gregg Williams beneficially own after these transactions?

After the reported purchases, Gregg Williams indirectly owned 29,781,952 Vivani shares and directly held 4,799,200 shares. A footnote explains he has voting and dispositive power over a total of 34,581,152 shares held directly and through several trusts and affiliated entities.

How are Gregg Williams’ Vivani Medical (VANI) holdings structured across entities?

His total 34,581,152-share beneficial ownership includes 4,799,200 shares held directly and shares held by the Gregg G. Williams 2006 Trust, Williams International Co. LLC, Sam Williams Family Investments LLC, and the Sam B. Williams 1995 Generation-Skipping Trust, over which he has voting and dispositive power.

What gross dollar amounts are associated with Gregg Williams’ Vivani Medical (VANI) private purchases?

The filing reports gross proceeds of $1,649,999.23 for the 1,601,941-share purchase at $1.03 and $333,334.26 for the 264,551-share purchase at $1.26. These figures reflect the total transaction values for the private sale agreements described in the footnotes.